Nurse NCPD

23rd Annual School of Breast Oncology® Curriculum

Joyce O’Shaughnessy, MD

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma - Learning Hub

Stay up to date with the latest advances in hematologic malignancies throug…

School of Breast Oncology® (SOBO) Slide & Lecture Library

Joyce O’Shaughnessy, MD

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Barbara Pro, MD; Saad Z. Usmani, MD, MBA, FACP, FASCO; Amer Zeidan, MD

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

Project ECHO®: Navigating CRS and ICANS Related to CAR T-Cell Therapy: Prevention, Grading, and Management in Practice

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP; Kyle T. Roberts, PA-C

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Krish Patel, MD; Matthew Ulrickson, MD

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Project ECHO®: Building Bridges in CAR T Care: Collaborative Pathways to Improve Patient Access and Navigate Referrals

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP; Katie Marcucci, DMSc, PA-C, …

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

John O. Mascarenhas, MD; Claire Harrison, MD, DM, FRCP, FRCPath; Raajit Ram…

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Webinar Series

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

Lori A. Leslie, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Krish Patel, MD; Tara Graff, DO, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Krish Patel, MD; Girish Kunapareddy, MD

Castleman Disease in Practice—Recognizing, Classifying, and Treating a Rare Disorder

July 28, 2026

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Krish Patel, MD; Premila Malhotra, MD

Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO; Kamel Abou Hussein, MD

Burst CME™: Elevating Care in the Management of IgA Nephropathy (IgAN) Nursing Track

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Project ECHO®: CAR T in Practice: Identifying Eligible Patients Across Hematologic Malignancies

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Ruben A. Mesa, MD, FACP; Andrew Kuykendall, MD; Sangeetha Venugopal, MD, MS

Cases and Conversations™: Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders

Katherine E. Di Palo, PharmD, MBA, MS; Nancy M. Albert, PhD, APRN-CCNS, CHF…

Tumor Board: Optimizing NSCLC Care—Leveraging the Latest Evidence on Targeted Therapy and Immuno-Oncology

Enriqueta Felip, MD, PhD; Justin Gainor, MD; Julia Rotow, MD; Urs Weber, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisbe…

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; Ja…

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, …

The Rapidly Changing Treatment Landscape in the Management of Atopic Dermatitis—A Place in Therapy for OX40-OX40L Inhibitors

Andrew Blauvelt, MD, MBA; Melinda Gooderham, MD, FRCPC

Selecting an Optimal Therapeutic Strategy for the Management of Atopic Dermatitis in Young Children

Elaine Siegfried, MD; Lawrence F. Eichenfield, MD

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us

Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD…

Obesity: New and Emerging Strategies to Optimally Manage a Chronic Disease

Scott Kahan, MD, MPH; Robert F. Kushner, MD, MS, DABOM; Christopher D. Stil…

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models

February 6, 2027

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

July 30, 2026

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham MD, FACP; Paolo Taran…

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; Paula A. Ugalde Figueroa, …

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Gabriela Hobbs, MD; Rami Komrokji, MD; Douglas A. Tremblay, MD

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, …

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Ghassan Abou-Alfa, MD, MBA; Riad Salem, MD, MBA; Rachna Shroff, MD, MS, FAS…

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, PhD

Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma

Samuel J. Klempner, MD, FASCO; Christian Baglini, MS, AGNP-BC; Jonathan N. …

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Lori A. Leslie, MD; Bachar Samra, MD

Medical Crossfire®: DLL3-Directed Therapies in Small Cell Lung Cancer—A Nursing-Centered Approach to a New Era of Care

Alissa J. Cooper, MD; Kelly Goodwin, NP; Stephanie J. McDonald, MSN, FNP-BC…

Houston Hematology Satellite Symposia

September 10, 2026

Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Heather McArthur, MD, MPH;…

Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

Mohamad Mohty, MD, PhD; Shaji K. Kumar, MD; Suzanne Lentzsch, MD, PhD; Phil…

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Lori A. Leslie, MD; Alex Mejia, MD

Show Me the Data®: Evolving Standards and New Frontiers in Ovarian Cancer

Ursula A. Matulonis, MD; Bradley J. Monk, MD, FACS, FACOG; Ritu Salani, MD,…